Friday, May 1, 2026

Is This the End for Park Sang-yong? Legal Battle Looms Over North Korean Remittance Case

Prosecutor Park Sang-yong is suspended amid allegations of coercion in the North Korea remittance case, claiming political motivations behind the action.

Dogecoin Surges 10% After Rumors of the Cryptocurrency Possibly Adopted as a Form of Payment

While Bitcoin is undergoing a modest rise, Dogecoin is soaring by over 10% due to news that X is likely to adopt it for payments.

Kim Yo-jong’s Dual Messaging Strategy: A Deep Dive into North Korea’s Political Tactics

Kim Yo-jong's statement reflects duality in North Korea's approach to South Korea, balancing appreciation and disconnection amidst ongoing tensions.

Tag: clinical trials

Samsung Bioepis Launches SBE303: The First ADC Drug Candidate Targeting Nectin-4 in Cancer Trials

Samsung Bioepis has begun Phase 1 trials for its ADC candidate SBE303, targeting solid tumors, set to continue until July 2030.

YH35995: A Game-Changer for Gaucher Disease? FDA Grants Orphan Drug Designation

Yuhan Corp's YH35995 for Gaucher disease receives orphan drug designation, enhancing its development for rare diseases with unmet needs.

Imeroprubart vs. Batoclimab: Which Treatment Will Revolutionize Graves’ Disease Management?

HanAll Biopharma's Imeroprubart targets Graves' disease, showing promise with IgG suppression and user-friendly auto-injector delivery.

JW Pharmaceuticals Secures Exclusive Rights for Innovative GLP-1 Drug Vopaglutide in South Korea

JW Pharmaceutical secures exclusive rights for Vopaglutide, a promising treatment for diabetes and obesity, with significant milestone payments.

GI-101A: Breakthrough Immuno-Oncology Drug Set for ASCO 2026 Presentation

GI Innovation's GI-101A will be presented at ASCO 2026, highlighting its clinical potential and significance in oncology.

Is A Breakthrough For Thyroid Eye Disease Still Out Of Reach?

HanAll Biopharma's Phase 3 trial of batoclimab for Thyroid Eye Disease failed to show statistical significance, but safety profiles remain consistent.

JW Pharmaceutical Secures Phase 1 Approval for Novel Hair Loss Treatment JW0061—What to Expect?

JW Pharmaceutical is investing in innovative hair loss treatments and expanding its drug portfolio, including successful cholesterol medications.

Alpha Tau Medical’s Alpha DaRT: A New Hope for Pancreatic Cancer Patients – What You Need to Know

Alpha Tau Medical will present clinical results of its DaRT technology for pancreatic cancer at DDW 2026, marking a significant milestone.

How AI Read CXR is Transforming Chest X-Ray Analysis: A Deep Dive into the First AI Medical Device Approved in Korea

South Korea's first generative AI medical device, AI Read X-ray, gains approval for interpreting X-rays with radiologist-level accuracy.

Exploring Cenobamate: How SK Biopharmaceuticals’ New Oral Suspension Benefits Adult Epilepsy Patients

SK Biopharmaceuticals submits NDA for Cenobamate oral suspension, enhancing treatment options for epilepsy patients with swallowing difficulties.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

Lunit and Selcarta Join Forces: Accelerating AI Biomarker Companion Diagnostics in 2026

Lunit partners with Selcarta to enhance AI-based biomarkers for diagnostics, aiming to streamline clinical trials and accelerate drug development.

HLB’s Liraglutide: A Game-Changer in Cholangiocarcinoma Treatment with FDA Priority Review

HLB's Elevar Therapeutics receives FDA Priority Review for lirafugratinib, a promising treatment for cholangiocarcinoma with a 47% response rate.

FDA’s Game-Changing Guidelines: What Asian Biotech Firms Must Know About Clinical Trial Efficiency

Clinical Trial Design is crucial for success in pharma; FDA's new rules could ease burdens but raise quality standards.

Top News

- Our Sponsors Ad -

Follow us